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Objective: A case with reversible symmetrical sensorineural hearing loss following hydroxychloroquine therapy is
described.
Case summary: A 57-year-old, human immunodeficiency virus (HIV) positive man was referred to the HIV clinic of
Imam Khomeini Hospital, Tehran with chief complaint of bilateral slowly progressive hearing loss starting from two
months ago. The man had history of rheumatoid arthritis diagnosed from 3 months ago and was administered
hydroxychloroquine 200 mg and prednisolone 5 mg twice daily. Audiometry test showed moderate to severe
neuronal hearing loss and reduced speech recognition in both ears of the patient. With suspicion of
hydroxychloroquine-induced hearing loss, this drug was discontinued. After 2 months of hydroxychloroquine
discontinuation, his audiometry findings were improved.
Discussion: A few cases of hydroxychloroquine-induced hearing loss have been reported. All of the cases were
non-HIV positive individuals. Irreversible hearing loss was developed following long-term therapy with
hydroxychloroquine. The present case was a HIV-positive man who developed hearing loss following short course
(one month) hydroxychloroquine therapy and his problem was resolved following discontinuation of
hydroxychloroquine and continuation of prednisolone.
Conclusions: Hydroxychloroquine-induced hearing loss may reversibly occur following short term therapy in HIV
patients.
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HydroxychloroquineIntroduction
Hydroxychloroquine (HQ), a quinoline compound, rarely
causes ototoxicity. Its ototoxicity is associated with varying
degree of destruction of the cochlear sensory hair cells, a
decrease in neuronal population, alteration in supporting
structures and atrophy and vacuolization of the stria
vascularis as a possible consequence of ischemia [1,2].
Clinically significant HQ-related adverse reactions includ-
ing retinopathy and other visual disorders are usually de-
tected during long-term therapy [3]. Deafness following
prolonged therapy with HQ has been also reported [4].
In the previous report, ototoxicity of HQ was irrevers-
ible and manifested by auditory dysfunction without
vestibular changes [5]. In the present case, HQ-induced* Correspondence: khalilih@tums.ac.ir
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reproduction in any medium, provided the orbilateral reversible hearing loss is described in a HIV
positive man suffering from rheumatoid arthritis (RA).Case report
A 57-year-old HIV positive man was referred to the HIV
clinic of Imam Khomeini Hospital, Tehran, Iran, with
chief complaint of bilateral slowly progressive hearing
loss starting from two months ago. He had no previous
cochleo-vestibular symptoms and the hearing loss was
described without tinnitus, vertigo or balance changes.
He had no history of head trauma prior to the beginning
of the hearing loss. He was a known case of HIV infec-
tion following blood transfusion from 2 years ago. In his
medical history, RA was diagnosed from 3 months ago
when he was receiving HQ 200 mg and prednisolone 5
mg twice daily. He did not consume any antiretroviral
supplements or herbal products.td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 1 The audiogram of the patient after 1 month of treatment with hydroxychloroquine.
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and CD4/CD8 ratio of 0.13. All the other routine labora-
tory parameters were within the normal range. Based on
the patient clinical status and his CD4 count, antiretroviral
regimen including lamivudine, zidovudine and efavirenz
was started. Also sulfamethoxazole/trimethoprim and iso-
niazid was considered for prophylaxis of pneumocystis
and tuberculosis respectively in this patient.
Otolaryngological consultation reported normal oto-
scopic and neurologic examinations for the patient. Pure-
tone (air and bone conduction) and speech audiometry
showed moderate to severe neuronal hearing loss and re-
duced speech recognition in his both ears (45 and 40 dB
in the right and left ears respectively) (Figure 1). Absence
of middle ear pathologic conditions was confirmed byRight ear 
Figure 2 The audiogram of the patient, 2 months after discontinuatiopneumatic otoscopy and tympanometry. Furthermore,
acoustic reflexes were latent in the patient.
With suspicious of HQ-induced hearing loss, the drug
was discontinued and prednisolone was continued to con-
trol his RA symptoms. Two months later, his audiometric
findings improved. Pure-tone and speech audiometry re-
vealed mild to moderate hearing loss and slight to mild
disability in speech recognition in the right and left ears,
respectively (Figure 2). His acoustic reflexes were still
latent.
Discussion
Idiopathic sudden sensorineural hearing loss usually
occurs 5–20 per 100,000 populations mostly due to
viral infections, vascular occlusion with microcirculatoryLeft ear
n of hydroxychloroquine.
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membrane breaks [6]. Some drugs may cause vestibuloco-
chlear toxicity. Chloroquine another quinoline compound
aggregates in melanocytes and results in variable injur-
ies to the cochlear sensory hair cells, decrease in neur-
onal population, loss of supporting hair cells, and
atrophy of stria vascularis. These changes might be
caused by an ischemic process [1,7]. There are some
reports about chloroquine-induced ototoxicity [7-9].
Severe chloroquine-induced cochleovestibular toxicity
was reported in a pregnant woman [8]. Absence of
inner and outer hair cells of the cochlea was also de-
tected in a child whose mother took chloroquine during
her pregnancy [9]. Scherbel et al. reported tinnitus, a
sense of imbalance and nerve deafness after prolonged
chloroquine administration [7].
Only a few cases of HQ-induced hearing loss have
been reported. First case was a 44-year-old woman and
the second case was a 44-year-old man with lupus ery-
thematous. Both of these patients developed irreversible
hearing loss following several years of HQ treatment [5].
The third patient was a 34-year-old woman with diagno-
sis of RA, who developed reversible, bilateral hearing
loss following five months of HQ therapy [10]. Another
report was unilateral sensorineural hearing loss in a
7-year-old girl with idiopathic pulmonary hamosidero-
sis. Her problem was diagnosed after 2 years of HQ
administration [11].
All of the previous cases were non-HIV positive individ-
uals. In these patients HQ-induced ototoxicity developed
following long term HQ administration. In most of them,
hearing loss was irreversible. Our case was a HIV-positive
man who developed hearing loss following short course
(one month) HQ therapy and his problem was resolved
following HQ discontinuation.
HQ is structurally related to chloroquine and shows
similar ototoxicity pattern. Chloroquine-induced hearing
loss is reversible if prompt chloroquine cessation and
steroid administration is done [12]. Our patient was
receiving prednisolone concomitant with HQ and it is
justifiable to suppose that the reversibility of his hear-
ing loss was due to concomitant administration of this
anti-inflammatory agent.
Our case is the first report of reversible symmetrical
hearing loss following HQ therapy in a HIV-infected pa-
tient. The patient received daily HQ with dose of 200 mg
twice daily for 3 months. No other causes of hearing loss
were detected in this patient. Hearing loss in HIV infected
persons may result from opportunistic infections such as
cryptococcal meningitis or neurosyphilis [13] and ototoxic
medications [14]. Although hearing loss was reported
following antiretroviral therapy [15], in our patient
these drugs were started two months after the beginning
of his hearing loss. There is no any difference inaudiometric findings in patients with RA compared with
non-RA subjects [16].
According to the Naranjo probability scale [17], hearing
loss in the present patient was probably related to HQ ad-
ministration. According to definition of adverse reaction
severity [18], that reaction was categorized as grade 3.
Corticosteroids are only confirmed effective treatment
of sudden sensorineural hearing loss. It is important to
notice that prednisone should be started as soon as pos-
sible after the onset of hearing loss [19].
In conclusion HQ-induced hearing loss may appear
following short-term administration especially in patients
with underlying viral infections and may be reversible by
corticosteroid therapy.
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